Federal Circuit affirms ruling on Regeneron inequitable conduct

28-07-2017

The US Court of Appeals for the Federal Circuit has affirmed a ruling of a lower court that found a patent owned by Regeneron unenforceable because of the biotech company’s inequitable conduct. 


US Court of Appeals for the Federal Circuit, Regeneron, patent, inequitable conduct, biotech, Merus

LSIPR